Arcturus Therapeutics Holdings Inc ARCT.OQ ARCT.O is expected to show a fall in quarterly revenue when it reports results on May 12 for the period ending March 31 2025
The San Diego California-based company is expected to report a 26.7% decrease in revenue to $27.876 million from $38.01 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Arcturus Therapeutics Holdings Inc is for a loss of $1.33 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $55.00, above its last closing price of $10.98.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.52 | -0.55 | -1.11 | Missed | -102.2 |
Sep. 30 2024 | -1.23 | -1.22 | -0.26 | Beat | 78.6 |
Jun. 30 2024 | -1.51 | -1.60 | -0.64 | Beat | 60 |
Mar. 31 2024 | -1.21 | -1.19 | -1.00 | Beat | 15.9 |
Dec. 31 2023 | -0.60 | -0.99 | -0.32 | Beat | 67.7 |
Sep. 30 2023 | -1.72 | -1.69 | -0.61 | Beat | 63.9 |
Jun. 30 2023 | -0.18 | -0.21 | -1.98 | Missed | -839.5 |
Mar. 31 2023 | 0.04 | 0.06 | 1.87 | Beat | 3,029.7 |
This summary was machine generated May 9 at 23:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)